RecruitingPhase 3LSD
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Sponsored by Definium Therapeutics US, Inc.
NCT ID
NCT06809595
Target Enrollment
250 participants
Start Date
2025-01-29
Est. Completion
2027-05
About This Study
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Conditions Studied
Interventions
- •Placebo
- •MM120 (LSD D-Tartrate)
Eligibility
Age:18 Years - 74 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness
Study Locations (36)
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Psychedelic Science Institute
Los Angeles, California, United States
West Los Angeles VA Medical Center
Los Angeles, California, United States
Cenexel-CNS
Torrance, California, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Sheppard Pratt Health System
Towson, Maryland, United States
Adams Clinical Boston
Boston, Massachusetts, United States
Princeton Medical Institute
Princeton, New Jersey, United States
+26 more locations